JP2023546759A - 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用 - Google Patents

腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用 Download PDF

Info

Publication number
JP2023546759A
JP2023546759A JP2023549958A JP2023549958A JP2023546759A JP 2023546759 A JP2023546759 A JP 2023546759A JP 2023549958 A JP2023549958 A JP 2023549958A JP 2023549958 A JP2023549958 A JP 2023549958A JP 2023546759 A JP2023546759 A JP 2023546759A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546759A5 (https=
Inventor
ハン，ハック
シュウ，シャオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023546759A publication Critical patent/JP2023546759A/ja
Publication of JP2023546759A5 publication Critical patent/JP2023546759A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
JP2023549958A 2020-10-23 2021-10-22 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用 Pending JP2023546759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104850P 2020-10-23 2020-10-23
US63/104,850 2020-10-23
PCT/US2021/056282 WO2022087435A1 (en) 2020-10-23 2021-10-22 Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof

Publications (2)

Publication Number Publication Date
JP2023546759A true JP2023546759A (ja) 2023-11-07
JP2023546759A5 JP2023546759A5 (https=) 2024-10-29

Family

ID=81290113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549958A Pending JP2023546759A (ja) 2020-10-23 2021-10-22 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用

Country Status (9)

Country Link
US (1) US20230391892A1 (https=)
EP (1) EP4232063A4 (https=)
JP (1) JP2023546759A (https=)
KR (1) KR20230112629A (https=)
CN (1) CN116744959A (https=)
AU (1) AU2021365528A1 (https=)
CA (1) CA3196077A1 (https=)
MX (1) MX2023004725A (https=)
WO (1) WO2022087435A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518064A (ja) * 2011-06-03 2014-07-28 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE469176T1 (de) * 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
HRP20181939T4 (hr) * 2013-03-20 2022-05-13 Genzyme Corporation Postupci za liječenje osteogenesis imperfecta
US10633423B2 (en) * 2014-06-13 2020-04-28 Affibody Ab IL-6-binding polypeptide complex
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518064A (ja) * 2011-06-03 2014-07-28 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer ce", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR BASIS OF DISEASE, vol. 1864, no. 3, JPN6025040884, 2018, pages 891 - 899, ISSN: 0005703410 *
"Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 170, no. 3, JPN6025040885, 1989, pages 655 - 663, ISSN: 0005703411 *

Also Published As

Publication number Publication date
US20230391892A1 (en) 2023-12-07
EP4232063A1 (en) 2023-08-30
AU2021365528A9 (en) 2025-04-10
EP4232063A4 (en) 2025-01-01
WO2022087435A1 (en) 2022-04-28
AU2021365528A1 (en) 2023-06-15
CN116744959A (zh) 2023-09-12
KR20230112629A (ko) 2023-07-27
MX2023004725A (es) 2024-02-23
CA3196077A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
JP7320571B2 (ja) 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
TWI826358B (zh) 用於治療肌肉萎縮和骨疾病的新型雜合ａｃｔｒｉｉｂ配體陷阱蛋白及其用途與生產方法
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
JP2023548399A (ja) Ｔｇｆ－ベータファミリーの複数のリガンドを阻害する能力を有する新規の二機能性多特異性アンタゴニストおよびその使用
JP2023546759A (ja) 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用
RU2851121C1 (ru) Новые бифункциональные мультиспецифические антагонисты, способные ингибировать множественные лиганды семейства tgf-бета, и их применения
RU2858732C2 (ru) Бифункциональные антагонисты активина/TGF-бета и RANKL и их применение
US20230391880A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
JP2023548346A (ja) アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用
CN116801895A (zh) 新颖的能够抑制TGF-β家族多于一种配体的双功能多特异性拮抗剂及其用途
CN116917330A (zh) 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途
RU2834707C9 (ru) Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
RU2834707C1 (ru) Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
JP2023504974A (ja) 抗ｔｉｒｃ７抗原結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260424